AdipoSeeds Inc.
- Biotech or pharma, therapeutic R&D
AdipoSeeds is a leader and pioneer in directly producing platelet-like cells (ASCL-PLC) from “donor-independent” human adipose-derived mesenchymal stem cell (MSC) lines (ASCL), without genomic modification. We seek strategic development partners for our allogeneic, off-the-shelf regenerative medicine pipeline for wound healing and platelet transfusion. Current target indications are:
1) Intractable skin ulcer: ADS-01 (Clinical stage);
2) Platelet Transfusion: ADS-02 (Pre-clincal);
3) Osteoarthritis, Tendon injury, etc.: (Pre-clinical)
)
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}